{"pub": "wsj", "url": "https://wsj.com/articles/new-gilead-sciences-cfo-expected-to-pursue-more-deals-to-expand-portfolio-11571175231?mod=rsswn", "downloaded_at": "2019-10-15 23:07:13.605333+00:00", "title": "New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio", "language": "en", "text": "Biopharmaceutical giant Gilead Sciences Inc. selected an internal candidate to become its next finance chief, filling a key position on its leadership team as the company looks to further expand its portfolio beyond its core HIV treatments.\n\nThe Foster City, Calif.-based company Tuesday said it appointed Andrew Dickinson as chief financial officer, effective Nov. 1. Mr. Dickinson, currently executive vice president for corporate development and strategy, joined Gilead in 2016 following a nine-year tenure in investment banking. He will succeed Robin Washington, who is set to retire from the CFO role but will remain in an advisory capacity until early next year. Ms. Washington\u2019s planned retirement was announced in April.\n\nChief Executive Daniel O\u2019Day \u2014who took the reins this year after a career at Roche Holding AG \u2014in recent months made several key appointments at Gilead, including a new chief medical officer and a new head of its commercial division. \u201cWith the new CEO, CMO and CFO now in place, this effectively marks the end of a transition period for the company,\u201d analysts at RBC Capital Markets LLC wrote in a note to clients.\n\nGilead described Mr. Dickinson as the architect behind the company\u2019s 2017 $11.9 billion acquisition of Kite Pharma Inc., a maker of cancer drugs, and its recent research and development collaboration with Belgium-based Galapagos NV, a company focusing on inflammation and immunology treatments.\n\nMr. Dickinson \u201ctransformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making,\u201d Gilead said in a statement.\n\nAnalysts expect Gilead to pursue more deals once Mr. Dickinson has established himself as CFO. \u201cThey are putting together a team of people who would be very capable of doing that,\u201d said Alethia Young, head of health-care research at Cantor Fitzgerald, a financial services firm. \u201cThey are messaging that by putting this type of CFO in place.\u201d\n\nGilead declined to comment beyond details included in a press release.\n\nGilead\u2019s balance sheet\u2014with $30.2 billion in cash, cash equivalents and marketable debt securities at the end of June\u2014provides Mr. Dickinson with ample flexibility, analysts said.\n\n\u201cThey have the balance sheet to do multiple deals with early-stage companies,\u201d said Mohit Bansal, a vice president for equity research at Citigroup Inc. Mr. Bansal said he expects the company to spend several billion dollars on transactions similar to the one with Galapagos.\n\nGilead has various options, including a continued expansion into oncology treatments, cures for hepatitis B or inflammation and immunology drugs, said Salim Syed, head of biotechnology research at Mizuho Americas LLC, a corporate and investment bank. \u201cThey have a CFO now that has a history as a mergers-and-acquisitions banker,\u201d Mr. Syed said. \u201cCapital allocation becomes a really important question at this point.\u201d\n\nBefore his time at Gilead, Mr. Dickinson worked for nine years at Lazard Ltd. , where he was global co-head of health-care investment banking, and at Myogen Inc., a biopharmaceutical company that was acquired by Gilead in 2006.\n\nGilead\u2019s shares rose 1.2% Tuesday to $65.30.\n\nWrite to Nina Trentmann at nina.trentmann@wsj.com", "description": "Biopharmaceutical giant Gilead Sciences selected an internal candidate to become its next finance chief, filling a key position on its leadership team as the company looks to further expand its portfolio beyond HIV treatments.", "authors": ["Nina Trentmann", "Nina.Trentmann Wsj.Com"], "top_image": "https://images.wsj.net/im-117234/social", "published_at": "2019-10-15"}